Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC
NCT ID: NCT04641130
Last Updated: 2020-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2017-07-13
2017-09-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure to birch pollen
Step 1: dose validation 16 subjects are exposed for 2 consecutive days (D1 + D2), to the same aerial concentration of Bet v1.
The main objective is achieved if the Abelson score is ≥ 5 on J1 or J2. If the main objective is achieved for the 60 ng/m3 concentration, 8 responder subjects will directly perform step 2.
If the main objective is not achieved for the 60 ng/m3 concentration, the subjects will be exposed between 7 to 10 days after exposure 1, to an allergen concentration of 120 ng/m3 (Exposure 2: D1 + D2).
Step 2: reproducibility Once the allergen concentration has been determined (step 1), 8 of the responder subjects from step 1 are exposed again to this same concentration, during 2 additional exposures (Exposure 3: D1 + D2 and Exposure 4: D1 + D2), at least 7 days apart.
A wash-out period of at least 7 days is observed between step 1 and 2. The duration of allergen exposure will be a maximum of 4 hours for all exposures.
Exposure to birch pollen in EEC
Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure to birch pollen in EEC
Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects affiliated to a social security scheme
* Subjects with birch pollen rhinitis and conjunctivitis with:
* A history of rhinoconjunctivitis for at least the last 2 consecutive pollen seasons.
* A positive skin prick-test to birch (wheal diameter \>6 mm compared to the negative control),
* Specific immunoglobulin E (IgE) for birch\> 0.1 kIU/l
* Women of childbearing potential must have a negative pregnancy test during the entire study period with an effective means of contraception: oral contraceptives, intrauterine device, condom with spermicide for at least one month before inclusion in the study and for the duration of the study. At each study visit and each exposure on D1, a urine pregnancy test will be performed.
* A positive conjunctival provocation test to birch during the screening visit at a dilution of 100IR/ml maximum
Exclusion Criteria
* Use of oral corticosteroids in the 4 weeks preceding inclusion in the study
* Use of biotherapy in the 4 months preceding inclusion in the study
* Desensitization to birch pollen in the last 5 years
* Uncontrolled chronic pathologies (hypertension, cardiac, respiratory, renal pathology).
* Active autoimmune disease
* Uncontrolled systemic hypertension
* Subjects who participated in another clinical study in the three months prior to inclusion
* Pregnancy and breast feeding
* Inability to understand and act upon the information provided
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alyatec
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédéric de Blay, Pr.
Role: PRINCIPAL_INVESTIGATOR
Alyatec
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alyatec
Strasbourg, Grand Est, France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Alyatec website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALY-002B
Identifier Type: -
Identifier Source: org_study_id